Kalaris Therapeutics (KLRS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Kalaris Therapeutics (KLRS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $75M, trading at
Kalaris Therapeutics (KLRS) has a market capitalization of approximately $75M, trading at
Kalaris Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Kalaris Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Kalaris Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Kalaris Therapeutics carries a debt-to-equity ratio of 0.02x and a current ratio of 12.14x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kalaris Therapeutics (KLRS) the key facts are: market cap $75M, 52-week range 2.14-11.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Kalaris Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.